Search results for "Blood"

showing 10 items of 5199 documents

Echocardiographic and angiographic evaluation of left ventricular function during percutaneous transluminal aortic valvuloplasty.

1992

Transesophageal echocardiography was used to study the effect of the balloon inflation on left ventricular function in 20 patients with critical aortic stenosis undergoing balloon valvuloplasty. Balloon inflation caused an increase of end-diastolic (15% to 34%) and end-systolic (57% to 72%) left ventricular volume. Left ventricular wall stress increased from 30 +/- 10 x 10(3) dyn/cm2 at diastole and 121 +/- 40 x 10(3) dyn/cm2 at systole to 44 +/- 11 x 10(3) dyn/cm2 and 191 +/- 55 x 10(3) dyn/cm2, respectively, when the balloon was inflated (P less than 0.05). Turbulent regurgitant jet across the mitral valve increased from 15 +/- 2% to 25 +/- 3% during balloon inflation (P less than 0.01). …

Aortic valveMalemedicine.medical_specialtymedicine.medical_treatmentDiastoleMyocardial InfarctionBalloonCoronary AngiographyVentricular Function LeftCatheterizationRisk FactorsMitral valveInternal medicineCoronary CirculationmedicineHumansSystoleCardiac OutputAgedAged 80 and overbusiness.industryHemodynamicsMitral Valve InsufficiencyBlood flowAortic Valve StenosisMiddle Agedmedicine.diseaseAortic valvuloplastyStenosismedicine.anatomical_structureEchocardiographyAortic Valvecardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessCatheterization and cardiovascular diagnosis
researchProduct

Controlling protein interactions in blood for effective liver immunosuppressive therapy by silica nanocapsules

2020

Immunosuppression with glucocorticoids is a common treatment for autoimmune liver diseases and after liver transplant, which is however associated with severe side-effects. Targeted delivery of glucocorticoids to inflammatory cells, e.g. liver macrophages and Kupffer cells, is a promising approach for minimizing side effects. Herein, we prepare core–shell silica nanocapsules (SiO2 NCs) via a sol–gel process confined in nanodroplets for targeted delivery of dexamethasone (DXM) for liver immunosuppressive therapy. DXM with concentrations up to 100 mg mL−1 in olive oil are encapsulated while encapsulation efficiency remains over 95% after 15 days. Internalization of NCs by non-parenchymal muri…

Apolipoprotein BCell SurvivalLiver cytologyPharmacologybehavioral disciplines and activitiesDexamethasoneNanocapsulesProinflammatory cytokine//purl.org/becyt/ford/1 [https]MiceDrug Delivery SystemsDrug StabilityNanocapsulesQuímica Coloidalmental disordersBlood plasma//purl.org/becyt/ford/1.4 [https]AnimalsHumansIMMUNOSUPPRESSIVE THERAPYTissue DistributionGeneral Materials ScienceColloidsImmunosuppression TherapybiologyClusterinChemistryCiencias QuímicasSILICA NANOCAPSULESSilicon DioxideBlood proteinsPROTEIN INTERACTIONSDEXAMETHASONELiverbiology.proteinPEGylationCytokinesCIENCIAS NATURALES Y EXACTASImmunosuppressive AgentsHeLa CellsNanoscale
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

2020

Several lines of evidence now attest that lipoprotein[a] (Lp[a]) is a significant risk factor for many cardiovascular disorders. This enigmatic lipoprotein, composed of a single copy of apolipoprotein B (apoB) and apolipoprotein[a] (apo [a]), expresses peculiar metabolism, virtually independent from lifestyle interventions. Several therapeutic options have hence been proposed for lowering elevated Lp[a] values, with or without concomitant effect on low density lipoprotein (LDL) particles, mostly encompassing statins, ezetimibe, nicotinic acid, lipoprotein apheresis, and anti-PCSK9 monoclonal antibodies. Since all these medical treatments have some technical and clinical drawbacks, a novel s…

Apolipoprotein Bmedicine.drug_classgovernment.form_of_governmentAntisense therapyHyperlipidemias030204 cardiovascular system & hematologyPharmacologyAntisense therapy; Apolipoprotein[a]; Cardiovascular disease; Lipoprotein[a]Monoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeLipoprotein[a]Internal MedicinemedicineHumans030212 general & internal medicineAntisense therapybiologybusiness.industryLipoprotein(a)Cardiovascular diseaseLipoproteins LDLchemistryConcomitantLow-density lipoproteinBlood Component Removalbiology.proteingovernmentlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein[a]Lipoprotein(a)Lipoproteinmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Vascular effects of diet supplementation with plant sterols.

2008

Objectives The purpose of this study was to evaluate vascular effects of diet supplementation with plant sterol esters (PSE). Background Plant sterol esters are used as food supplements to reduce cholesterol levels. Their effects on endothelial function, stroke, or atherogenesis are not known. Methods In mice, plasma sterol concentrations were correlated with endothelial function, cerebral lesion size, and atherosclerosis. Plasma and tissue sterol concentrations were measured by gas-liquid chromatography-mass spectrometry in 82 consecutive patients with aortic stenosis. Results Compared with those fed with normal chow (NC), wild-type mice fed with NC supplemented with 2% PSE showed increase…

Apolipoprotein EAortic valveMalemedicine.medical_specialtyDiet therapyArteriosclerosisCardiovascular SystemBrain Ischemiachemistry.chemical_compoundMiceEzetimibeRisk FactorsInternal medicinepolycyclic compoundsmedicineAnimalsHumansEndotheliumAgedCholesterolbusiness.industryPhytosterolsSterolMice Inbred C57BLEndocrinologymedicine.anatomical_structurechemistryCirculatory systemDietary Supplementslipids (amino acids peptides and proteins)FemalePlant PreparationsCardiology and Cardiovascular MedicinebusinessBlood vesselmedicine.drugJournal of the American College of Cardiology
researchProduct

Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model.

2012

Background The blood-brain barrier (BBB) represents an insurmountable obstacle for most drugs thus obstructing an effective treatment of many brain diseases. One solution for overcoming this barrier is a transport by binding of these drugs to surface-modified nanoparticles. Especially apolipoprotein E (ApoE) appears to play a major role in the nanoparticle-mediated drug transport across the BBB. However, at present the underlying mechanism is incompletely understood. Methodology/Principal Findings In this study, the uptake of the ApoE-modified nanoparticles into the brain capillary endothelial cells was investigated to differentiate between active and passive uptake mechanism by flow cytome…

Apolipoprotein EDrugs and DevicesDrug Research and DevelopmentLipoproteinsMaterials Sciencelcsh:MedicinePlasma protein bindingBiologyBlood–brain barrierBiochemistryFlow cytometryApolipoproteins EMaterial by AttributeMiceApolipoproteins EDrug Delivery Systemsddc:570Cell Line TumormedicineAnimalsHumansNanotechnologyPharmacokineticsReceptorlcsh:ScienceBiologySerum AlbuminBrain DiseasesMultidisciplinaryMicroscopy Confocalmedicine.diagnostic_testlcsh:RBrainEndothelial CellsProteinsBiological TransportFlow CytometryCell biologymedicine.anatomical_structureBlood-Brain BarrierNanoparticles for drug delivery to the brainLDL receptorNanoparticlesMedicinelcsh:QProtein BindingResearch ArticleBiotechnologyPLoS ONE
researchProduct

Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

2007

Background— We have recently demonstrated that activity of red blood cell glutathione peroxidase-1 is inversely associated with the risk of cardiovascular events in patients with coronary artery disease. The present study analyzed the effect of glutathione peroxidase-1 deficiency on atherogenesis in the apolipoprotein E-deficient mouse. Methods and Results— Female apolipoprotein E-deficient mice with and without glutathione peroxidase-1 deficiency were placed on a Western-type diet for another 6, 12, or 24 weeks. After 24 weeks on Western-type diet, double-knockout mice (GPx-1 −/− ApoE −/− ) developed significantly more atherosclerosis than control apolipoprotein E-deficient mice. Moreover…

Apolipoprotein Emedicine.medical_specialtyGPX1AntioxidantApolipoprotein Bmedicine.medical_treatmentLipoproteinsApoptosisBlood Pressuremedicine.disease_causeNitric OxideMitochondria HeartMonocyteschemistry.chemical_compoundMiceApolipoproteins EGlutathione Peroxidase GPX1SuperoxidesInternal medicinePeroxynitrous AcidmedicineAnimalsAortaCell Proliferationchemistry.chemical_classificationMice KnockoutReactive oxygen speciesGlutathione PeroxidaseMembranesbiologyGlutathione peroxidaseGlutathioneAtherosclerosisEndocrinologyPhenotypechemistryImmunologybiology.proteinDisease ProgressionFemaleCardiology and Cardiovascular MedicineReactive Oxygen SpeciesOxidation-ReductionOxidative stressArteriosclerosis, thrombosis, and vascular biology
researchProduct

Reduced VLDL clearance in ApoeNpc1 mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels

2010

Niemann-Pick type C1 (NPC1) promotes the transport of LDL receptor (LDL-R)-derived cholesterol from late endosomes/lysosomes to other cellular compartments. NPC1-deficient cells showed impaired regulation of liver_X receptor (LXR) and sterol regulatory element-binding protein (SREBP) target genes. We observed that Apoe(-/-)Npc1(-/-) mice displayed a marked increase in total plasma cholesterol mainly due to increased VLDL, reflecting decreased clearance. Although nuclear SREBP-2 and Ldlr mRNA levels were increased in Apoe(-/-)Npc1(-/-) liver, LDL-R protein levels were decreased in association with marked induction of proprotein convertase subtilisin/kexin type 9 (Pcsk9) and inducible degrade…

Apolipoprotein EreceptorCholesterol VLDLLDL/metabolismMacrophages Peritoneal/cytologyBiochemistryMiceEndocrinologyhemic and lymphatic diseasesReceptorsOrphan Nuclear Receptors/geneticspolycyclic compoundsnuclear receptorCells CulturedResearch ArticlesLiver X ReceptorsMice KnockoutCulturedSterol Regulatory Element Binding Protein 2/geneticslipoproteinSerine EndopeptidasesIntracellular Signaling Peptides and ProteinsLamin Type AOrphan Nuclear ReceptorsTriglycerides/bloodCholesterolLiverProteins/geneticsKexinlipids (amino acids peptides and proteins)Proprotein ConvertasesProprotein Convertase 9Sterol Regulatory Element Binding Protein 1Niemann-Pick diseaseSterol Regulatory Element Binding Protein 2medicine.medical_specialtyCellsKnockoutUbiquitin-Protein LigasesReceptors LDL/metabolismSerine Endopeptidases/geneticsQD415-436BiologyCholesterol/blooddigestive systemApolipoproteins ELiver/physiologySterol Regulatory Element Binding Protein 1/geneticsNiemann-Pick C1 ProteinInternal medicinemedicineAnimalsPeritoneal/cytologyCholesterol VLDL/metabolismUbiquitin-Protein Ligases/geneticsLiver X receptorTriglyceridesMacrophagesPCSK9Proteinsnutritional and metabolic diseasesVLDL/metabolismLamin Type A/metabolismCell BiologySterol regulatory element-binding proteinEndocrinologyReceptors LDLLDL receptorMacrophages PeritonealSterol regulatory element-binding protein 2atherosclerosisApolipoproteins E/geneticsLipoproteinJournal of Lipid Research
researchProduct

Opposite vascular activity of (R)-apomorphine and its oxidised derivatives. Endothelium-dependent vasoconstriction induced by the auto-oxidation meta…

2003

We have synthetised a series of oxidised apomorphine derivatives (orto and para quinones 2-5), in order to analyse their vascular activity. We have performed radioligand binding assays on rat cortical membranes and functional studies on rat aortic rings. Instead the relaxant activity exhibited by (R)-apomorphine, o-quinones 2, 4, show contractile activity dependent on endothelium in rat aortic rings. Compound 2, the main metabolite of (R)-apomorphine auto-oxidation, was the product which showed enhanced contractile activity by a complex mechanism related to activation of Ca(2+) channels through release and/or inhibition of endothelial factors. Moreover, this compound disrupts the endothelia…

ApomorphineCalcium Channels L-TypeEndotheliumMetaboliteRadioligand Assaychemistry.chemical_compoundDrug DiscoverymedicineAnimalsVasoconstrictor AgentsEnzyme InhibitorsRats WistarAortaCerebral CortexPharmacologyDose-Response Relationship DrugbiologyOrganic ChemistryQuinonesStereoisomerismGeneral MedicineReceptors Adrenergic alphaReceptors GABA-AAcetylcholineIn vitroRatsApomorphineNitric oxide synthasemedicine.anatomical_structureBiochemistrychemistryVasoconstrictionBiophysicsbiology.proteinFemaleEndothelium VascularNitric Oxide Synthasemedicine.symptomOxidation-ReductionVasoconstrictionAcetylcholineBlood vesselmedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct